What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
1. Q4 EPS loss at 62¢ beat the 74¢ consensus. Loss improved from 64¢ last year. 2. Revenue hit $201.8M, a 30% increase YoY. Sales outpaced the $192.14M consensus. 3. Test volumes surged: 57,300 oncology and 11,050 biopharma tests. Growth driven by increased clinical activity. 4. Medicare reimbursement for Guardant360 LDT improved to $5,000. Guidance for FY2025 revenue aligns with consensus. 5. Analysts upgraded GH with raised price targets from $39 to $59. Investors remain cautious amid a 10.60% stock drop.